Home Cart Sign in  
Chemical Structure| 119425-90-0 Chemical Structure| 119425-90-0

Structure of Loureirin B
CAS No.: 119425-90-0

Chemical Structure| 119425-90-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Loureirin B is one of the active components in Sanguis draxonis.

Synonyms: LB; LrB

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Loureirin B

CAS No. :119425-90-0
Formula : C18H20O5
M.W : 316.35
SMILES Code : O=C(C1=CC=C(O)C=C1)CCC2=C(OC)C=C(OC)C=C2OC
Synonyms :
LB; LrB
MDL No. :MFCD07781421
InChI Key :ZPFRAPVRYLGYEC-UHFFFAOYSA-N
Pubchem ID :189670

Safety of Loureirin B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Loureirin B

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK

  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 10 µM To study the inhibitory effect of LrB on Kv1.3 currents Front Immunol. 2023 Apr 24;14:1094649
RAW264.7 cells 10 μM 24 hours Loureirin B inhibits RANKL-induced NFATc1 transcriptional activity. Theranostics. 2019 Jul 3;9(16):4648-4662
Bone marrow macrophages (BMMs) 1 μM to 10 μM 5 days Loureirin B inhibits RANKL-induced osteoclast differentiation and F-actin belt formation without cytotoxicity. Theranostics. 2019 Jul 3;9(16):4648-4662
PBMCs 10 µM 60 minutes To study the inhibitory effect of LrB on inflammatory cytokine release in PBMCs Front Immunol. 2023 Apr 24;14:1094649
Jurkat T cells 10 µM 60 minutes To study the inhibitory effect of LrB on IL-2 release in Jurkat T cells Front Immunol. 2023 Apr 24;14:1094649
HEK293 T cells 3, 10, 30 μM To investigate the inhibitory effects of Loureirin B on STIM1/Orai1 currents. Results showed that Loureirin B inhibited STIM1/Orai1 currents in a concentration-dependent manner with an IC50 of 17.11 ± 2.17 μM. Front Pharmacol. 2021 Jun 25;12:685092
Jurkat T cells 0.01, 0.1, 1 μM 1 hour To investigate the inhibitory effects of Loureirin B on Ca2+ influx and IL-2 secretion in Jurkat T cells. Results showed that Loureirin B significantly inhibited Ca2+ influx and IL-2 secretion. Front Pharmacol. 2021 Jun 25;12:685092
rat liver microsome (RLM) 30 μg/mL 45 minutes To investigate the metabolic features of LB in rat liver microsome, including metabolites identification, elimination kinetics and metabolizing CYP450. Front Pharmacol. 2018 Oct 12;9:1130
Ins-1 cells 10^-5-10^-9 mol/L 4 hours To investigate the effect of LB on insulin secretion in Ins-1 cells, the results showed that LB significantly promoted insulin secretion in Ins-1 cells. J Cell Mol Med. 2021 Jan;25(2):855-866
KKU-M156 21.26 ± 3.17 µg/mL 72 hours Evaluate the cytotoxicity of Loureirin B against KKU-M156 cells, showing moderate cytotoxicity BMC Complement Med Ther. 2022 Aug 11;22(1):217
HepG2 20.02 ± 0.46 µg/mL 72 hours Evaluate the cytotoxicity of Loureirin B against HepG2 cells, showing moderate cytotoxicity BMC Complement Med Ther. 2022 Aug 11;22(1):217
bone marrow macrophages (BMMs) 10 mM 1 hour To investigate the inhibitory effect of Loureirin B on the differentiation of BMMs into osteoclasts, it was found that Loureirin B inhibits the differentiation of BMMs by suppressing the phosphorylation of JNK and p38 kinases in the MAPK signaling pathway. Sci Rep. 2022 Aug 23;12(1):14382
Rat hepatic stellate cells 50 and 100 ng/μl 48 hours Loureirin B significantly promoted the apoptosis of HSCs in a dose-dependent manner. Cell Mol Biol Lett. 2018 Aug 2;23:35
Rat hepatic stellate cells 100 ng/μl 24, 48 and 72 hours Loureirin B significantly inhibited the proliferation of HSCs in a time-dependent manner. Cell Mol Biol Lett. 2018 Aug 2;23:35
Rat hepatic stellate cells 12.5, 25, 50, 100, 200 or 400 ng/μl 48 hours Loureirin B significantly inhibited the proliferation of HSCs in a dose-dependent manner. Cell Mol Biol Lett. 2018 Aug 2;23:35
Primary human dermal fibroblast cells 0-350 µM 24 and 48 hours Evaluate the cytotoxicity of Loureirin B on primary human dermal fibroblast cells, showing no cytotoxic effects. Life (Basel). 2025 Mar 3;15(3):396
H1299 cells 0-140 µM 24 hours Evaluate the effect of Loureirin B on the viability of H1299 cells, showing no toxicity at 0-140 µM. Life (Basel). 2025 Mar 3;15(3):396
A549 cells 0-140 µM 24 hours Evaluate the effect of Loureirin B on the viability of A549 cells, showing no toxicity at 0-140 µM. Life (Basel). 2025 Mar 3;15(3):396

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Ovariectomy (OVX)-induced osteoporosis model Intraperitoneal injection 4 mg/kg Every 2 days for 6 weeks Loureirin B prevents OVX-induced osteoporosis and preserves bone volume by repressing osteoclast activity and function. Theranostics. 2019 Jul 3;9(16):4648-4662
Wistar rats Collagen-induced arthritis (CIA) model Intraperitoneal injection 30 mg/kg Once daily for 15 days To study the therapeutic effect of LrB on CIA rats Front Immunol. 2023 Apr 24;14:1094649
Sprague-Dawley rats TNBS-induced Crohn's disease rat model Oral gavage 25, 50 and 100 mg/kg Once daily for 28 days LB prolonged the survival time of TNBS-induced rats and alleviated colonic damage in a dose dependent manner. Besides, LB remarkably ameliorated TNBS-induced inflammatory response, reversed the established fibrosis, and improved the apoptosis induced by TNBS. Chin Med. 2020 Jan 6;15:2
SD rats PCOS-IR rat model Intraperitoneal injection 10, 20, 40 mg/kg·d Once daily for 4 weeks Loureirin B upregulated GPR120, LKB1, and AMPK protein expression, downregulated NLRP3 and Caspase-1 protein expression, reduced insulin resistance and chronic inflammation, and ameliorated histopathological changes in ovarian tissues in PCOS rats, suggesting its potential as a treatment for PCOS. Int J Mol Sci. 2024 Oct 17;25(20):11146

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.16mL

0.63mL

0.32mL

15.81mL

3.16mL

1.58mL

31.61mL

6.32mL

3.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories